China Pharma Holdings, Inc. CPHI
- Market cap
- $31.8M
- P/E
- 0.0×
Follow CPHI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.00 | 75.00 | 85.00 | 105.00 | 120.00 | 200.00 | 45.00 | 4.00 | 1.30 | 1.18 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 175.00 | 165.00 | 725.00 | 290.00 | 700.00 | 815.00 | 265.00 | 60.00 | 6.50 | 3.40 |
High Price
|
|||
| 385 | 296 | 252 | 242 | 248 | 246 | 244 | 239 | 231 | 221 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 16 | 13 | 12 | 11 | 11 | 10 | 8 | 7 | 5 | 4 |
Revenue
|
|||
| 20.67% | 18.68% | 16.02% | 13.57% | 17.97% | 3.62% | (6.09%) | (4.01%) | (43.84%) | (3.18%) |
Gross Margin
|
|||
| (9) | (19) | (11) | (21) | (3) | (3) | (4) | (3) | (5) | (3) |
EBT
|
|||
| (56.99%) | (144.98%) | (88.07%) | (189.51%) | (26.38%) | (35.26%) | (49.02%) | (43.91%) | (104.58%) | (76.92%) |
EBT Margin
|
|||
| (9) | (19) | (11) | (21) | (3) | (3) | (4) | (3) | (5) | (3) |
Net Income
|
|||
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |
Depreciation
|
|||
| 178.56 | 151.52 | 141.41 | 125.27 | 124.62 | 104.46 | 77.11 | 20.72 | 2.59 | 0.97 |
Revenue/Sh
|
|||
| (105.00) | (220.00) | (125.00) | (240.00) | (35.00) | (35.00) | (38.00) | (9.10) | (2.70) | (0.74) |
Earnings/Sh
|
|||
| 33.21 | 9.65 | 21.58 | 6.98 | (0.49) | (2.71) | (3.90) | (2.07) | (0.23) | 0.03 |
Cash Flow/Sh
|
|||
| (2.22) | (1.57) | (0.59) | (1.56) | (9.95) | (4.75) | (3.82) | (0.03) | (0.17) | (0.03) |
Capex/Sh
|
|||
| 30.99 | 8.08 | 21.00 | 5.42 | (10.43) | (7.45) | (7.72) | (2.10) | (0.40) | 0.00 |
Free CF/Sh
|
|||
| 675.56 | 493.94 | 346.32 | 105.94 | 91.79 | 65.20 | 40.82 | 22.03 | 4.44 | 5.30 |
Book Value/Sh
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.70 | 0.56 | 0.92 | 0.96 | 1.81 | 2.30 | 0.58 | 0.29 | 0.89 | 1.25 |
PS Ratio
|
|||
| 0.19 | 0.17 | 0.38 | 1.13 | 2.45 | 3.68 | 1.10 | 0.27 | 0.52 | 0.23 |
PB Ratio
|
|||
| 1.11 | 1.05 | 1.25 | 1.24 | 2.19 | 2.78 | 1.22 | 0.43 | 1.28 | 1.97 |
EV/Sales
|
|||
| 22.38 | (11.28) | (151.42) | (9.27) | (8.39) | (11.21) | (3.60) | (1.13) | (2.47) | (184.67) |
EV/FCF
|
|||
| 3 | 1 | 2 | 1 | 0 | 0 | 0 | (1) | 0 | 0 |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| 3 | 1 | 2 | 0 | (1) | (1) | (1) | (1) | (1) | 0 |
FCF
|
|||
| 7 | 3 | (1) | (4) | (6) | (1) | (7) | (1) | (2) | (5) |
Working Cap'
|
|||
| 10 | 9 | 7 | 4 | 5 | 10 | 2 | 2 | 2 | 2 |
Total Debt
|
|||
| 6 | 6 | 4 | 3 | 4 | 5 | 0 | 1 | 2 | 2 |
Net Debt
|
|||
| 59 | 43 | 30 | 9 | 8 | 6 | 4 | 7 | 8 | 23 |
Sh' Equity
|
|||
| (10.49%) | (27.84%) | (20.41%) | (61.24%) | (13.23%) | (15.53%) | (19.65%) | (17.98%) | (30.21%) | (13.89%) |
ROA
|
|||
| (7.81%) | (23.58%) | (19.06%) | (103.64%) | (13.17%) | (16.79%) | (47.32%) | (20.46%) | (30.16%) | (8.31%) |
ROIC
|
|||
| (13.96%) | (37.81%) | (29.34%) | (104.99%) | (33.25%) | (48.49%) | (77.08%) | (52.43%) | (62.31%) | (20.91%) |
ROE
|
|||
China Pharma Holdings, Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| RMTI Rockwell Medical, Inc. | $34.5M | 0.0× | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $40.1M | — | Compare |
| AYTU Aytu BioPharma, Inc. | $25.1M | 0.0× | Compare |
| IXHL Incannex Healthcare Inc. | $40.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TXMD TherapeuticsMD, Inc. | $24.7M | 0.0× | Compare |
| UPC Universe Pharmaceuticals INC | $23.5M | 0.0× | Compare |
| SCYX SCYNEXIS, Inc. | $45.0M | 0.0× | Compare |
| BFRI Biofrontera Inc. | $17.8M | 0.0× | Compare |
China Pharma Holdings, Inc. (CPHI) key facts
- China Pharma Holdings, Inc. (CPHI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on NYSE American.
- China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024.
- As of September 25, 2026, CPHI traded at $0.75, a market capitalization of $31.8 million.
- Return on equity was −20.9% and debt-to-equity 0.05.
China Pharma Holdings, Inc. (CPHI) Latest News
23 Jul
China Pharma Holdings closed a $5.0 million registered direct offering. The capital raise supplies operating funds yet triggers share dilution that moderately affects near-term valuation and sentiment.
22 Jul
China Pharma Holdings priced a $5 million registered direct offering. Registered direct offering supplies $5 million in fresh capital that supports operations and may influence share structure.
18 Dec
China Pharma Holdings, Inc. completes full redemptions under convertible note agreement with Streeterville. The completion of full redemptions under the convertible note agreement may moderately influence the company's financial performance.
19 Aug
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. The launch of a new medical treatment device for a prevalent condition in China is expected to have a significant impact on the company's future performance and market positioning.
29 Nov
China Pharma Holdings, Inc. announced completion of third-party testing for Dry Eye Disease therapeutic device. The successful completion of third-party testing for the therapeutic device and preparation for market launch is a significant development that could have a major impact on the company's future performance and market position.
23 Aug
China Pharma Holding Inc (CPHI) may be undervalued but poses risks with low Altman Z-score and declining revenues. The article highlights potential risks and challenges that could significantly impact the company's trajectory and investor sentiment.
9 Aug
China Pharma's Candesartan tablets passed quality and efficacy evaluation for generic drugs. Passing the evaluation will enhance competitiveness in government procurement.